BG
ADVM

BlackRock Group’s Adverum Biotechnologies ADVM Stock Holding History

BlackRock Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-378
Closed -$31K – 3002
2015
Q3 		$31K Buy
378
+90
+31% +$11.5K ﹤0.01% 2916
2015
Q2 		$47K Buy
288
+77
+36% +$26K ﹤0.01% 2871
2015
Q1 		$85K Buy
+211
New +$89.2K ﹤0.01% 2685
2014
Q4 		– Sell
-489
Closed -$167K – 2870
2014
Q3 		$167K Buy
+489
New +$145K ﹤0.01% 2492

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock Group's ADVM Position: Q4 2015 in Review

BlackRock Group sold out of Adverum Biotechnologies (ADVM) in Q4 2015, closing a stake of 378 shares — an estimated $31K sold.

BlackRock Group first reported a position in ADVM in Q3 2014 and held it in 4 quarters. The position peaked at $167K in Q3 2014. 76 funds tracked by Wall St. Rank hold ADVM as of Q4 2015.

  • BlackRock Group reported no remaining Adverum Biotechnologies position as of Q4 2015 after selling out during the quarter.
  • BlackRock Group sold 378 Adverum Biotechnologies shares in Q4 2015, an estimated $31K.
  • BlackRock Group first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 4 quarters.
  • BlackRock Group's Adverum Biotechnologies position peaked at $167K in Q3 2014.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2015.

Based on BlackRock Group's 13F filing for Q4 2015, filed 11 Feb 2016.